Product Overview
Compound: FOXO4‑DRI (D‑Retro‑Inverso peptide, “Proxofim”)
Form: 10 mg vial, ≥99 % purity; cell-penetrating senolytic targeting FOXO4–p53 interaction :contentReference[oaicite:1]{index=1}
For research use only—NOT for human or veterinary use.
Batch tested ≥99 % purity by HPLC. COA available upon request—contact providers@theratideusa.com.
- Senolytic action: Disrupts FOXO4–p53 binding to trigger selective apoptosis in senescent cells :contentReference[oaicite:2]{index=2}.
- Cartilage health & osteoarthritis: Removes senescent chondrocytes (PDL9) and reduces cartilage-degrading markers MMP12/MMP13 :contentReference[oaicite:3]{index=3}.
- Kidney & testicular rejuvenation: Improves renal function and restores testosterone levels & Leydig cell health in aged mice via senescent cell clearance :contentReference[oaicite:4]{index=4}.
- Anti-fibrosis & oncology uses: Shows reduced lung fibrosis in bleomycin models and lethal effect on senescent tumor cells while sparing healthy ones :contentReference[oaicite:5]{index=5}.
All findings are from preclinical in vitro or animal models; no human clinical data available yet.
What is FOXO4‑DRI used for?
Research focuses on senolytic therapy, tissue rejuvenation, osteoarthritis, fibrosis reversal, renal and testicular regeneration.
How does it work?
Acts as a D‑retro‑inverso peptide to displace p53 from FOXO4 in senescent cells, triggering apoptosis while sparing healthy cells :contentReference[oaicite:6]{index=6}.
Any human trials?
Currently limited to lab/animal studies—no published human data yet :contentReference[oaicite:7]{index=7}.
Suggested handling?
Reconstitute freshly; store lyophilized at ≤ –20 °C; protect from light and moisture.
For laboratory research use only—not for human or veterinary use, nor as a dietary supplement.
Safety: Use appropriate lab protocols, protective gear, and secure storage.
FDA Notice: These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
